Arimoclomol

DRUG11 trials

Sponsors

CytRx, University of Miami, Richard Barohn, MD, ZevraDenmark

Conditions

Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS)Gaucher Disease, Type 1Gaucher Disease, Type 3Inclusion Body MyositisNiemann-Pick Disease, Type C

Phase 2

A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS

CompletedNCT00244244

CytRxAmyotrophic Lateral Sclerosis (ALS)

Start: 2005-10-31End: 2007-01-31Target: 80Updated: 2012-02-09

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

WithdrawnNCT00561366

CytRxAmyotrophic Lateral Sclerosis

Updated: 2012-02-09

Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis

CompletedNCT00706147

University of MiamiAmyotrophic Lateral Sclerosis

Start: 2009-01-31End: 2016-11-30Updated: 2019-01-11

Arimoclomol in Sporadic Inclusion Body Myositis

CompletedNCT00769860

Richard Barohn, MDInclusion Body Myositis

Start: 2008-09-30End: 2012-09-30Updated: 2017-01-19

Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C

CompletedNCT02612129

ZevraDenmarkNiemann-Pick Disease, Type C

Start: 2016-06-14End: 2024-10-31Updated: 2024-11-29

Study of Arimoclomol in Inclusion Body Myositis (IBM)

CompletedNCT02753530

ZevraDenmarkInclusion Body Myositis

Start: 2017-08-16End: 2021-01-11Updated: 2023-05-10

Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3

TerminatedNCT03746587

ZevraDenmarkGaucher Disease, Type 1, Gaucher Disease, Type 3

Start: 2018-06-06End: 2021-10-15Updated: 2023-01-11

Phase 3

Arimoclomol in Amyotropic Lateral Sclerosis

CompletedNCT03491462

ZevraDenmarkAmyotrophic Lateral Sclerosis

Start: 2018-07-31End: 2020-12-18Updated: 2023-08-24

Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

TerminatedNCT03836716

ZevraDenmarkAmyotrophic Lateral Sclerosis

Start: 2019-09-19End: 2021-07-02Updated: 2023-08-24

Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial

TerminatedNCT04049097

ZevraDenmarkInclusion Body Myositis

Start: 2019-05-20End: 2021-11-15Updated: 2023-09-15

Unknown Phase

Early Access Program With Arimoclomol in US Patients With NPC

ZevraDenmarkNiemann-Pick Disease, Type C

Updated: 2024-08-16

Related Papers

Long-term efficacy and safety of arimoclomol in Niemann-Pick disease type C: Final results of the phase 2/3 NPC-002 48-month open-label extension trial.

2025-07-07

Efficacy results from a 12-month double-blind randomized trial of arimoclomol for treatment of Niemann-Pick disease type C (NPC): Presenting a rescored 4-domain NPC Clinical Severity Scale.

2025-05-281 citations

Measurement properties of the Inclusion Body Myositis Functional Rating Scale

Journal of Neurology Neurosurgery & Psychiatry2024-07-025 citations

Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

2024-05-2019 citations

Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial.

2023-10-0123 citations

Identification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1.

2023-01-3117 citations

Efficacy and safety of arimoclomol in <scp>Niemann‐Pick</scp> disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatment

Journal of Inherited Metabolic Disease2021-08-2185 citations

Validation of the 5-domain Niemann-Pick type C Clinical Severity Scale

Orphanet Journal of Rare Diseases2021-02-1244 citations

Clinical disease progression and biomarkers in Niemann–Pick disease type C: a prospective cohort study

Orphanet Journal of Rare Diseases2020-11-2325 citations

Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive <i>SOD1</i> ALS.

2018-01-24102 citations